Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: Retrospective analysis of 9095 patients

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 1, 2015, Pages 99-107

  De Felice, K M ^a   Novotna, M ^a,b   Enders, F T ^a   Faubion, W A ^a   Tremaine, W J ^a   Kantarci, O H ^a   Raffals, L E ^a  

^a MAYO CLINIC   (United States)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGH RISK PATIENT; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC INFLAMMATORY DEMYELINATING DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; ULCERATIVE COLITIS; UNITED STATES; AGED; COLITIS, ULCERATIVE; DEMYELINATING DISEASES; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; RISK;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; DEMYELINATING DISEASES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MINNESOTA; RETROSPECTIVE STUDIES; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84915756113     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12997     Document Type: Article

References (34)

1. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
2. Hanauer S, Feagan B, Lichtenstein G, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
4. Sandborn W, Feagan B, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
5. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257.
6. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2013; 146: 85.
7. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009; 29: 286-97.
8. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-4.
9. Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-65.
10. Mir Subias A, Garcia-Lopez S, Sebastian Torres B, Ollero Domenche L, Garcia Gamez A, Gomollon F. Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease. Gastroenterol Hepatol 2013; 36: 81-5.
11. Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004; 10: 28-31.
12. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-36.
13. Kimura K, Hunter SF, Thollander MS, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc 2000; 75: 802-6.
14. Green C, Elliott L, Beaudoin C, Bernstein CN. A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol 2006; 164: 615-23; discussion 24-8.
15. Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol 2010; 28: 623-67.
16. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-8.
17. Pappa HM, Gordon CM, Saslowsky TM, et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 2006; 118: 1950-61.
18. Westall FC. Molecular mimicry revisited: gut bacteria and multiple sclerosis. J Clin Microbiol 2006; 44: 2099-104.
19. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006; 5: 924-31.
20. Geissler A, Andus T, Roth M, et al. Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet 1995; 345: 897-8.
21. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129: 819-26.
22. Deepak P, Stobaugh D, Sherid M, Sifuentes H, Ehrenpreis E. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther 2013; 38: 388-96.
23. Dubcenco E, Ottaway CA, Chen DL, Baker JP. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy. Eur J Gastroenterol Hepatol 2006; 18: 565-6.
24. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
25. Freeman HJ, Flak B. Demyelination-like syndrome in Crohn's disease after infliximab therapy. Can J Gastroenterol 2005; 19: 313-6.
26. O'Donnell S, Murphy S, Anwar MM, et al. Safety of infliximab in 10 years of clinical practice. Eur J Gastroenterol Hepatol 2011; 23: 603-6.
27. Ouakaa-Kchaou A, Gargouri D, Trojet S, et al. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn's disease. J Crohns Colitis 2009; 3: 131-3.
28. Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010; 9: 188-93.
29. Van Assche G, Lewis J, Lichtenstein G, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011; 106: 1594.
30. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
31. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol [Review] 2005; 58: 840-6.
32. Lichtenstein G, Hanauer S, Sandborn W; Practice Parameters Committee of American College of G. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465.
33. Kornbluth A, Sachar D; Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501.
34. Andersen NN, Caspersen S, Jess T, Munkholm P. Occurrence of demyelinating diseases after anti-TNFalpha treatment of inflammatory bowel disease: a Danish Crohn Colitis Database study. J Crohns Colitis 2008; 2: 304-9.